Pharmaceutical Processing World

  • Home
  • Regulatory
    • Recalls
  • Pharmaceutical Processing
  • Facility
  • Supply Chain
  • Equipment and Materials
  • Contract Manufacturing
  • Advertise
  • SUBSCRIBE

AstraZeneca faces profitability dip in Q3 2023 despite revenue bump; bets big on obesity

By Brian Buntz | November 13, 2023

AstraZenecaCambridge, UK–based AstraZeneca continued its strong growth trajectory in Q3 2023, expanding its cardiometabolic and obesity pipeline with a focus on GLP-1 receptor agonists. In particular, AstraZeneca has a licensing agreement with Eccogene for ECC5004, a potential oral GLP-1RA for obesity and cardiometabolic conditions, represents the company’s strategic focus on this emerging therapeutic area, which Lilly and Novo Nordisk currently dominate.

Pascal Soriot, CEO of the company noted he was “excited” about the acceleration of the company’s cardiometabolic and obesity pipeline with the licensing agreement for ECC5004, “a potential best-in-class oral GLP-1RA.”

ECC5004 has an oral formulation, in contrast to Novo Nordisk’s Wegovy (semaglutide) and the recently approved Lilly’s Zepbound (tirzepatide), which are injectables. This oral GLP-1 receptor agonist could potentially improve patient compliance and accessibility in treating obesity and type 2 diabetes. While Novo Nordisk won FDA approval in 2019 for Rybelsus, an oral semaglutide formulation from Novo Nordisk. Both are GLP-1 receptor agonists, but Rybelsus is currently FDA approved only for managing type 2 diabetes. Novo Nordisk has a phase 3 study underway for oral semaglutide in obesity.

ECC5004 is now in phase 1 testing in healthy volunteers and patients with type 2 diabetes. Early data from this trial have shown encouraging results in terms of glucose and body weight reduction. AstraZeneca plans to conduct a phase 2 test for the molecule in 2024, viewing it as a potential monotherapy and as part of combinations for a variety of cardiometabolic conditions.

Additionally, AstraZeneca is working with Regeneron to develop small-molecule weight loss drugs targeting a newly discovered protein, GPR75. The particular focus of the partnership is to explore potential of small molecules to treat obesity. The GPR75 protein is a member of the G-protein-coupled receptor family.

Snapshot of the company’s recent financial performance

In the first nine months of 2023, the AstraZeneca’s total revenue was $33.787 billion, up 5%, with a 15% increase excluding COVID-19 medicines​​. The company was early to the COVID-19 vaccine race, but abandoned its plans to introduce its vaccine in the U.S.

  • Core product sales gross margin: 82%, a two percentage point bump.
  • Core operating margin: Increased to 35%, up by three percent.
  • Core EPS: Up 17% to $5.80.
  • Guidance for FY 2023: The company expects total revenue to increase by a mid-single-digit percentage, with low-teens percentage growth expected excluding COVID-19 medicines.

AstraZeneca achieved its 2014 target of reaching $45 billion in revenue by 2023, a year early. The company was able to hit that target largely as a result of the acquisition of Alexion Pharmaceuticals and robust sales in its cancer medicine division.

In an earnings call, Soriot highlighted the success in oncology, especially in China, and noted the integration of new assets like Enhertu and DS-1062 in collaboration with Daiichi Sankyo Co. Ltd. Its oncology business reported product sales of $12,692 million in the first nine months of 2023, accounting for one-fifth of total sales and marking a 38% increase in actual terms and 17% in constant exchange rates (CER). Medications such as Tagrisso and Imfinzi were major sales drivers. Tagrisso alone raked in $4.4 billion and Imfinzi had $3.1 billion in sales.

Over the past five days, AstraZeneca’s stock has seen a slight increase of 0.094%, hitting $63.73.

About The Author

Brian Buntz

The pharma and biotech editor of WTWH Media, Brian is a veteran journalist with more than 15 years of experience covering an array of life science topics, including clinical trials, drug discovery and development and medical devices. Before coming to WTWH, he served as content director focused on connected devices at Informa. In addition, Brian covered the medical device sector for 10 years at UBM. At Qmed, he overhauled the brand’s news coverage and helped to grow the site’s traffic volume dramatically. He had previously held managing editor roles on two of the company’s medical device technology publications. Connect with him on LinkedIn or email at bbuntz@wtwhmedia.com.

Tell Us What You Think! Cancel reply

Related Articles Read More >

Genentech roche
Roche, Genentech to build $700M drug manufacturing plant in North Carolina
These are the logos of Otsuka Medical and ICU Medical.
ICU Medical, Otsuka Pharmaceutical Factory launch joint IV supply chain venture
Amgen
Amgen to spend $900M to expand U.S. biopharma manufacturing
Roche
Roche to invest $50B in U.S. over next five years
“ppw
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news, technologies, and developments in Pharmaceutical Processing.

DeviceTalks Tuesdays

DeviceTalks Tuesdays

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Pharmaceutical Processing World
  • Subscribe to our E-Newsletter
  • Contact Us
  • About Us
  • R&D World
  • Drug Delivery Business News
  • Drug Discovery & Development
  • DeviceTalks
  • MassDevice
  • Medical Design & Outsourcing
  • MEDICAL TUBING + EXTRUSION
  • Medical Design Sourcing
  • Medtech100 Index
  • R&D 100 Awards

Copyright © 2025 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Pharmaceutical Processing World

  • Home
  • Regulatory
    • Recalls
  • Pharmaceutical Processing
  • Facility
  • Supply Chain
  • Equipment and Materials
  • Contract Manufacturing
  • Advertise
  • SUBSCRIBE